Short Interest Update on Peregrine Pharmaceuticals (PPHM)

Peregrine Pharmaceuticals (PPHM) : The short interest in Peregrine Pharmaceuticals (PPHM) has changed with an increase of 77,730 shares and the open interest is 6%. From 1,294,420 short positions on Jul 29, 2016, the shorts increased to 1,372,150 shares by August 15, 2016. There are 2 more days left for the expiry and the daily trading volume of the stock is 590,100 shares. The total interest of shorts is 0.6% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.

Peregrine Pharmaceuticals (NASDAQ:PPHM): The stock opened at $0.37 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.38 for the day. The stock traded down to $0.36 during the day, due to lack of any buying support eventually closed down at $0.37 with a loss of -0.81% for the day. The stock had closed at $0.37 on the previous day. The total traded volume was 636,803 shares.


Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.